NCT05555823View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 23, 2022

Primary Completion Date

July 20, 2023

Study Completion Date

July 20, 2023

Conditions
Healthy
Interventions
DRUG

ATR-002

300 mg tablets for oral intake

DRUG

Placebo

matching tablets for oral intake

DRUG

Repaglinide

0,5 mg tablets for oral intake

DRUG

Celecoxib

100 mg capsules for oral intake

Trial Locations (1)

Unknown

Atriva study site, Neu-Ulm

Sponsors
All Listed Sponsors
lead

Atriva Therapeutics GmbH

INDUSTRY

NCT05555823 - Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib | Biotech Hunter | Biotech Hunter